[go: up one dir, main page]

MX2021007003A - Método para tratar el cáncer. - Google Patents

Método para tratar el cáncer.

Info

Publication number
MX2021007003A
MX2021007003A MX2021007003A MX2021007003A MX2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A MX 2021007003 A MX2021007003 A MX 2021007003A
Authority
MX
Mexico
Prior art keywords
cell
subject
cancer
ezh2
expression
Prior art date
Application number
MX2021007003A
Other languages
English (en)
Other versions
MX394629B (es
Inventor
Heike Keilhack
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2021007003A publication Critical patent/MX2021007003A/es
Publication of MX394629B publication Critical patent/MX394629B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar o aliviar un síntoma de un trastorno, p. ej., una evasión inmunológica, disfunción inmunológica inducida por células cancerosas, respuesta inmunológica reducida, inflamación reducida, expresión disminuida de un complejo principal de histocompatibilidad (MHC), o cáncer, caracterizado por una actividad y/o expresión aberrante, regulada erróneamente o incrementada del potenciador del Zeste homólogo 2 (EZH2) en una célula o sujeto en necesidad del mismo, poniendo en contacto la célula o administrando al sujeto una cantidad terapéuticamente eficaz de un inhibidor de EZH2.
MX2021007003A 2014-10-16 2015-10-16 Método para tratar el cáncer. MX394629B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064948P 2014-10-16 2014-10-16
US201462065590P 2014-10-17 2014-10-17
PCT/US2015/056022 WO2016061507A1 (en) 2014-10-16 2015-10-16 Method for treating cancer

Publications (2)

Publication Number Publication Date
MX2021007003A true MX2021007003A (es) 2022-08-09
MX394629B MX394629B (es) 2025-03-24

Family

ID=55747431

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007003A MX394629B (es) 2014-10-16 2015-10-16 Método para tratar el cáncer.
MX2017004969A MX383635B (es) 2014-10-16 2015-10-16 Método para tratar el cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017004969A MX383635B (es) 2014-10-16 2015-10-16 Método para tratar el cáncer.

Country Status (13)

Country Link
US (5) US9889138B2 (es)
EP (1) EP3206688A4 (es)
JP (4) JP2017532338A (es)
KR (1) KR102397720B1 (es)
CN (2) CN112168967A (es)
AU (3) AU2015331729A1 (es)
BR (1) BR112017007738B1 (es)
CA (1) CA2963149A1 (es)
EA (1) EA201790845A1 (es)
IL (4) IL289947B2 (es)
MX (2) MX394629B (es)
SG (2) SG11201702488YA (es)
WO (1) WO2016061507A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9688665B2 (en) 2012-10-15 2017-06-27 Epizyme, Inc. Methods of treating cancer
IL289947B2 (en) * 2014-10-16 2024-06-01 Epizyme Inc Method for treating cancer
US10786511B2 (en) 2014-11-17 2020-09-29 Epizyme, Inc. Method for treating cancer
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
WO2016201328A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
SG10201909199PA (en) 2015-08-24 2019-11-28 Epizyme Inc Method for treating cancer
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
CN110730819A (zh) 2016-10-26 2020-01-24 索尼克马斯特有限公司 肌肉谱系细胞的改善产生及其治疗用途
KR101913693B1 (ko) * 2016-12-14 2018-10-31 사회복지법인 삼성생명공익재단 SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019018635A1 (en) 2017-07-19 2019-01-24 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT
EP3678663A4 (en) 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
US11319302B2 (en) * 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
WO2025121958A1 (ko) 2023-12-07 2025-06-12 서울대학교산학협력단 Sirt1 억제제를 포함하는 연골육종의 치료 또는 재발 방지용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036915A (en) 1911-05-25 1912-08-27 Joseph Schindler Utilizing exhaust-steam.
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
WO2008103763A2 (en) * 2007-02-20 2008-08-28 Sequenom, Inc. Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
AU2011298987B2 (en) * 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
ES2718900T3 (es) * 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
BR112014025508B1 (pt) 2012-04-13 2020-11-17 Eisai R&D Management Co., Ltd. forma de sal de um inibidor de histona metiltransferase ezh2 humana
MX367793B (es) 2012-04-13 2019-09-06 Epizyme Inc Terapia de combinación para tratar cáncer.
CN103690531A (zh) * 2012-09-27 2014-04-02 烟台大学 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
JP6461803B2 (ja) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド 置換ベンゼン化合物
US9688665B2 (en) 2012-10-15 2017-06-27 Epizyme, Inc. Methods of treating cancer
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZOL COMPOUNDS
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EA038869B1 (ru) 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
JP2016533364A (ja) * 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
ES2863996T3 (es) * 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
LT3157527T (lt) * 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
IL289947B2 (en) * 2014-10-16 2024-06-01 Epizyme Inc Method for treating cancer

Also Published As

Publication number Publication date
IL251411B (en) 2020-08-31
US10946024B2 (en) 2021-03-16
AU2015331729A1 (en) 2017-04-13
JP2017532338A (ja) 2017-11-02
CN112168967A (zh) 2021-01-05
CN106794177A (zh) 2017-05-31
SG10201903356XA (en) 2019-05-30
MX2017004969A (es) 2017-07-19
MX394629B (es) 2025-03-24
US10369155B2 (en) 2019-08-06
IL289947B2 (en) 2024-06-01
KR20170070140A (ko) 2017-06-21
IL289947A (en) 2022-03-01
US20210267990A1 (en) 2021-09-02
NZ730365A (en) 2024-03-22
JP2023109922A (ja) 2023-08-08
SG11201702488YA (en) 2017-04-27
US20160346293A1 (en) 2016-12-01
KR102397720B1 (ko) 2022-05-13
BR112017007738B1 (pt) 2023-04-11
IL276545A (en) 2020-09-30
EP3206688A1 (en) 2017-08-23
MX383635B (es) 2025-03-14
AU2022221580A1 (en) 2022-09-22
US20200009152A1 (en) 2020-01-09
US9889138B2 (en) 2018-02-13
IL310279A (en) 2024-03-01
IL276545B (en) 2022-02-01
US20250152598A1 (en) 2025-05-15
BR112017007738A2 (pt) 2018-01-30
WO2016061507A1 (en) 2016-04-21
EA201790845A1 (ru) 2017-08-31
US20180133224A1 (en) 2018-05-17
AU2021200995B2 (en) 2022-06-02
EP3206688A4 (en) 2018-06-13
IL289947B1 (en) 2024-02-01
CA2963149A1 (en) 2016-04-21
IL251411A0 (en) 2017-05-29
JP2020097615A (ja) 2020-06-25
AU2021200995A1 (en) 2021-03-11
JP2021105022A (ja) 2021-07-26

Similar Documents

Publication Publication Date Title
MX2021007003A (es) Método para tratar el cáncer.
MX2022001123A (es) Inhibidor de pd-1 para usarse en el tratamiento de cancer de piel.
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX394355B (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017004558A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MA45780B1 (fr) Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate
MX2019003235A (es) Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MY203831A (en) Treatment and diagnosis of inflammatory disorders
EA201692155A1 (ru) МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
WO2015134603A3 (en) Methods for treating cancer
AR108413A1 (es) Métodos de tratamiento de síndrome mielodisplásico con inhibidores de farnesiltransferasa
LT2016100A (lt) Dimerinis antikūno fragmentas, neutralizuojantis vaginolizino citolitinį aktyvumą
EA201990411A1 (ru) Способы лечения рака предстательной железы
UY36563A (es) Metodo para mejorar la terapia con agonista del receptor gabab
UY35317A (es) Compuesto de ciclopropanoamina